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ABSTRACT
Background: Albuminuria is a marker for renal and 
cardiovascular (CV) risk, allowing early diagnosis of 
subjects with elevated renal and CV risk. 
Objective: This study aimed to estimate the cost-
effectiveness and budget impact of various population-
based screen-and-treat scenarios for elevated albuminuria 
levels (ie, microalbuminuria) in the Netherlands.
Methods: A multistate transition Markov model was 
developed to simulate the natural course of albuminuria-
based disease progression to dialysis and occurrence of 
CV events. Several population-based strategies directed 
at screening for elevated albuminuria were evaluated. 
These strategies depended on urinary albumin concen-
tration (UAC), urinary albumin excretion (UAE), and 
age. Transition probabilities were derived from the 
observational community-based Prevention of Renal 
and Vascular End Stage Disease (PREVEND) cohort 
study. Health care costs (in year-2008 euros) and life-
years gained were calculated over an 8-year period. In 
the base-case analysis, we analyzed screening for and 
treatment of microalbuminuria. Screening for microal-
buminuria involved prescreening for UAC ≥20 mg/L, 
followed by a confirmation test for UAE ≥30 mg/d. 
Other options based on combinations of albuminuria 
for UAC prescreening (no prescreening, and ≥10, ≥20, 
≥100, and ≥200 mg/L) and UAE confirmation test (≥15, 
≥30, and ≥300 mg/d) for treatment were investigated 
in scenario analyses. Furthermore, these various strate-
gies based on UAC and UAE values were analyzed 
in different subgroups based on age (all ages, aged 
≥50 years, and aged ≥60 years).
Results: The PREVEND study included 8592 Dutch 
residents aged 28 to 75 years at the time of initial 
screening. Among a hypothetical cohort of 1000 subjects 
identified and treated in the base-case analysis, it was 
estimated (based on PREVEND follow-up data) that, 
in the screening/treatment and no-screening scenarios, 
76 versus 124 CV events occurred, 16 versus 27 CV deaths, 
and 3 versus 5 dialysis cases, respectively. The per-person 
difference in net costs for screening was calculated at 
€926 (€2003 vs €1077), and prevention of CV deaths 
was estimated to gain 0.0421 discounted life-year per 
person. Correspondingly, the cost-effectiveness was 
estimated at €22,000 per life-year gained. In the base-
case analysis, probabilistic sensitivity analysis indicated 
that the likelihood of cost-effectiveness of a screen-and-
treat strategy was 54%, 90%, and 95% for a maximum 
acceptable cost-effectiveness threshold of €20,000, 
€50,000, and €80,000 per life-year gained, respectively. 
Higher albuminuria thresholds for screening and start 
of treatment further improved the cost-effectiveness but 
reduced the overall health gains achieved. Limiting 
screening to those subjects aged ≥50 and ≥60 years 
resulted in more favorable cost-effectiveness compared 
with population-based screening without age restriction.
Conclusions: Our analyses suggest the potentially 
favorable cost-effectiveness of population-based screen-
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minuria (ie, microalbuminuria or macroalbumin- 
uria) would be most likely to result in an optimal 
cost-effectiveness (ie, most effective scenario for relative 
low costs) for screening the general Dutch population. 
Second, targeting screening to specific age groups may 
be more cost-effective than screening the overall popula-
tion. Obviously, both aspects are crucial in designing a 
screening program. There is only limited evidence re-
garding the cost-effectiveness of screening for elevated 
albuminuria; existing studies for the general population 
were further hampered by the fact that they considered 
the possible benefits of prevention of renal disease alone, 
and not CV disease.16–18 Furthermore, economic analyses 
can be limited if only data from randomized clinical 
trials are included.12
The aim of this study was therefore to estimate the 
cost-effectiveness and budget impact of various population- 
based screen-and-treat scenarios directed at several 
levels of albuminuria, targeting several age groups, and 
including CV as well as renal outcomes, to identify the 
most favorable screening strategy. For this purpose, we 
used data from a prospective, observational study.
METHODS
The current analysis was designed to calculate the cost-
effectiveness of a nationwide one-off screening (ie, one 
screening, not repeated as a periodic screening) for al-
buminuria in the general Dutch population. A Markov 
model was developed using data from the observational 
Prevention of Renal and Vascular End Stage Disease 
(PREVEND) study.19,20 In the model, disease progres-
sion and mortality were quantified by annual transition 
probabilities, representing the disease progression or 
mortality. Supported by actual observational data used, 
we assumed that the disease processes can be progres-
sive, as well as regressive. The annual transition prob-
abilities and mortality rates were based on data from 
the PREVEND study.
Population
The PREVEND study was a prospective study de-
signed to investigate the impact of albuminuria on the 
development of renal and CV events in the general 
population. Details of this study have been published 
elsewhere.21,22 Eligible inhabitants of the city of Gron-
ingen, the Netherlands, were invited to participate 
(~80,000 persons). Subjects for detailed study were 
selected from the 40,856 participating individuals from 
this general population. A cohort aged 28 to 75 years, 
ing for albuminuria in the general Dutch population. 
The results offer health care decision-makers new tools 
for considering actual implementation of such screening. 
(Clin Ther. 2010;32:1103–1121) © 2010 Excerpta 
Medica Inc.
Key words: cost-effectiveness, screening, microalbu-
minuria, cardiovascular disease, renal disease.
INTRODUCTION
End-stage renal disease and cardiovascular (CV) disease 
are major and growing public health problems, resulting 
in increasing financial burdens to society.1,2 Early di-
agnosis and timely start of treatment are essential goals 
to delay progression to end-stage renal disease and to 
prevent CV events.3,4
Urinary albumin excretion (UAE) values between 0 
and 15 mg/d are generally considered to be normal. 
Overall, albuminuria >15 mg/d (particularly microal-
buminuria [UAE ≥30 mg/d] and macroalbuminuria 
[UAE ≥30 mg/d]) has been reported to be both associ-
ated with significantly higher renal and CV risk.5,6 
Several studies established that reducing albuminuria 
using pharmaceuticals—typically with agents that in-
terfere with the renin–angiotensin–aldosterone system 
(RAAS)—is associated with a reduced incidence of CV 
and renal adverse outcomes in diabetic and hypertensive 
populations, as well as in the general population.6–12 
Previously, screening for elevated albuminuria was 
recommended as routine measurement among those in 
primary practice with CV and renal risk.6 Therefore, it 
may be worthwhile to implement population-based 
screening for and early treatment of albuminuria in 
high-risk populations (eg, hypertension, diabetes) or 
the general population to prevent CV and renal disease 
by adequate treatment.3,4,13,14 Such active screening 
targeted at specific subgroups or even screening of the 
general population would require efficient selection 
strategies and adequate testing methods.3,4,15 Various 
screening approaches have been advocated or applied, 
such as screening by means of a dipstick albuminuria 
self-test at home or by sending a urine sample to a 
central laboratory.3 After a positive test result, individu-
als are advised to visit their primary care provider for 
a confirmation test and additional routine renal and 
CV-risk profiling, which potentially result in treatment.
However, before such screening strategies can be 
implemented, several issues should be explored. First, 
it is not yet known what threshold for elevated albu-
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alysis. Long-term costs and effects of an 
albuminuria-based screen-and-treat intervention relied 
on estimations of the initial distribution of a patient 
cohort over albuminuria-based model states and as-
sumptions about how patients move between these 
health states. These movements—known as transition 
probabilities—are affected by the intervention of interest 
potentially resulting in different health outcomes.
The model used in this analysis simulated a cohort 
of 1000 hypothetical subjects with elevated albuminuria 
that were identified based on screening the general 
population. Subjects could switch between albuminuria 
states, to the other health states, or remain in the same 
health state. In our base-case analysis, we performed 
simulations in the Markov model for 8 years, which we 
considered a sufficient time for renal and CV events to 
occur in the selected population, whereas the relatively 
short time horizon (vs a lifetime horizon) enhanced 
plausibility, predictive value, and validity of the results. 
Also, an 8-year follow-up coincided with the duration 
of the PREVEND study and data availability for the 
PREVEND cohort.
Transition Probabilities
Transition probabilities for CV events and dialysis 
were calculated following a time-to-first-event approach. 
In particular, we included time to occurrence of the first 
outcome (ie, CV morbidity, CV mortality, dialysis, or 
non-CV mortality) or time until the initiation of anti-
hypertensive therapy or the last contact date.
For modeling purposes, the PREVEND cohort data 
could be considered a characteristic one in which indi-
viduals were monitored through time within irregular 
measurement intervals that varied over individuals. 
Furthermore, the information that was collected in the 
subsequent monitoring visits after baseline screening re-
flected the health state of the individual at the moment of 
the visit. The health state at the specific moment of the 
visit did not provide information regarding possible health-
state changes during the time period between visits. In 
other words, during screening visits, albuminuria- 
defined states could be determined, but the exact transi-
tion time point between states was unknown. In contrast, 
health outcomes were documented with the exact date 
of an event, including death. Therefore, we chose to use 
a multistate Markov approach that included all avail-
able prospective data (eg, albuminuria measurements, 
health outcomes) of individuals included for the 
PREVEND study.28 This approach offered the opportunity 
enriched for subjects with higher levels of albuminuria, 
was drawn from these individuals. A total of 8592 subjects 
gave written informed consent and were included in the 
baseline screening that took place between 1997 and 
1998. The prevalence of microalbuminuria and the 
prevalence of chronic kidney disease were found to be 
comparable in different country-specific settings.3,19,23 
These subjects subsequently visited an outpatient de-
partment with ~3-year intervals for follow-up screening. 
The subsequent screenings allowed actual transitions 
to be observed and subsequently to be recalculated on 
an annual basis. Also, among the 8592 subjects included 
for baseline screening, full pharmacy data were available 
for 8296 participants through linkage with the pharmacy 
dispensing records of IADB.nl, a database comprising 
Dutch prescription data.24 All subjects included in the 
PREVEND study gave informed consent to link with 
pharmacy-dispensing data.
Inclusion and exclusion criteria were defined to ap-
proach the natural course of disease progression with 
respect to albuminuria (Figure 1). Pharmacy-dispensing 
records were used to exclude subjects with previous use 
of RAAS-intervening agents. For all subjects, we ex-
cluded the time period after initiation of any type of 
antihypertensive to calculate the transition probabilities. 
Obviously, initiation of antihypertensives was likely to 
influence the natural course of disease progression. 
Following the anatomical–therapeutic–chemical (ATC) 
classification, initiation of antihypertensives was defined 
as ≥1 prescription for an antihypertensive (ATC code C02), 
diuretic (ATC code C03), β-blocker (ATC code C07), 
calcium-channel blocker (ATC code C08), or RAAS-
intervening agents (ATC code C09) during follow-up.25
Model Design
A Markov model was used to simulate the natural 
course of albuminuria progression and regression for 
the general population in Windows Excel 2003 (Mi-
crosoft Corporation, Redmond, Washington).26,27 The 
current Markov model consisted of 8 disease states that 
reproduced renal disease progression to dialysis and 
incidence of CV events (Figure 2). In the model, we ap-
plied 4 albuminuria-based states for the progression of 
renal disease: low normoalbuminuria (UAE <15 mg/d), 
high normoalbuminura (UAE 15–30 mg/d), microalbu-
minuria (UAE 30–300 mg/d), and macroalbuminuria 
(UAE ≥300 mg/d).6 The model additionally comprised 
4 outcome states defined as CV morbidity, CV mortality, 
all-cause mortality (other than CV mortality), and di-
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to progress, regress, or remain in the same albuminuria-
based state within this time interval. Health-outcomes 
states were considered absorbing states, which did not 
allow subjects to go through the albuminuria-based 
model after an event.
Outcome Definitions
Among the observed population, the incidences of 
CV morbidity, CV mortality, dialysis, or non-CV death 
were registered during follow-up. The PREVEND da-
tabase was linked to the database of the national registry 
of renal replacement therapy to obtain information 
about the status of end-stage renal disease (eg, dialysis, 
renal transplantation).31 Data on hospitalization for 
CV morbidity were obtained from the Dutch national 
registry of hospital stays.32 Causes of death were ob-
tained from the Dutch Central Bureau of Statistics.33 
All data were coded according to the International 
Classification of Diseases, Ninth Revision (ICD-9) and 
the classification of interventions. CV events were de-
fined according to the major adverse CV events criteria 
as acute myocardial infarction (ICD-9 code 410), acute 
and subacute ischemic heart disease (ICD-9 code 411), 
subarachnoid hemorrhage (ICD-9 code 430), intracere-
bral hemorrhage (ICD-9 code 431), other intracranial 
to account for changes in albuminuria levels (eg, as-
suming a certain pattern) between 2 measurements. 
Therefore, our multistate Markov model allowed for 
estimating transition probabilities from data with ir-
regular time intervals between measurements (albumin- 
uria) and health outcomes (CV disease and dialysis).28,29 
In particular, transition probabilities for 3 age- 
dependent groups (all subjects, aged ≥50 years, aged 
≥60 years) were estimated using the freely available R 
software MSM package.30 The principles of the method 
for calculating transition probabilities based on a discrete 
multistate Markov model in continuous time have been 
described in detail elsewhere.28–30 Therefore, we only 
present the overall principles.
The transition probabilities are, in principle, estimated 
based on the transition intensities derived from the 
original data, reflecting the rates of a transition from 
one health state to another. Central to this approach 
was calculating a transition probability matrix that 
included all possible transition probabilities. The transi-
tion probability matrix could be calculated by taking 
the exponent of the transition intensity matrix. Further-
more, transitions between states were assumed to occur 
at any time (discrete events in continuous time) within 

















Figure 2.  Structure of a multistate Markov model to simulate the natural course of albuminuria-based disease 
progression to dialysis and occurrence of cardiovascular events in the Netherlands. UAE = urinary 
albumin excretion.
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The effectiveness of ACEI treatment in prevent- 
ing CV events was derived from the randomized clini- 
cal PREVEND Intervention Trial (PREVEND IT).10 
PREVEND IT showed that fosinopril was associated 
with a 40% lower incidence of the primary end point 
of CV mortality and hospitalization for CV morbidity 
versus no treatment in a population of generally healthy 
subjects with albuminuria. In an observational set- 
ting, comparable reductions in CV events after initia- 
tion of antihypertensive treatment (especially with 
RAAS-intervening agents) were recently described for 
subjects with hypertension and elevated albuminuria 
levels, reinforcing the previously mentioned clinical trial 
findings.34 It was assumed in the model that subjects 
with elevated albuminuria were not yet treated or not 
treated well, based on the findings of the previously 
mentioned studies among heterogeneous popula- 
tions with or without background therapies.10,34 Ef-
fectiveness estimates of RAAS agents on the prevention 
of end-stage renal disease were not available for the 
general population and were therefore assumed to be 
the same as for CV events. These effectiveness assump-
tions were varied in univariate and probabilistic sensi-
tivity analyses.
The treatment effect on the progression and regres-
sion between the different albuminuria states was derived 
from the observational PREVEND data, following the 
method previously described by Brantsma et al.35 Brants-
ma et al found a net regression in albuminuria for the 
general Dutch population. For the purpose of the cur-
rent study, a comparable analysis was conducted to 
evaluate the effect of initiating RAAS-intervening agents 
on the progression or regression in UAE relative to no 
such treatment and/or no start of other antihypertensives. 
These relative differences in disease progression were 
applied to our Markov model to reflect the effect of 
screening with targeted intervention versus no screening 
on the transition probabilities between albuminuria-
based health states.
Costs, Cost-Effectiveness, and Budget Impact
Cost-effectiveness was estimated from the health care 
perspective, including medical costs only. Effects in 
terms of life-years gained (LYGs) were estimated based 
on the extension of life expectancy resulting from in-
tervention within the applied time horizon of 8 years. 
Costs of screening and treatment minus savings on CV 
events and dialysis were divided by the number of LYGs 
to render the cost-effectiveness ratio (ie, net cost per 
hemorrhage (ICD-9 code 432), occlusion or stenosis 
of the precerebral (ICD-9 code 433) or cerebral arteries 
(ICD-9 code 434), coronary artery bypass grafting or 
percutaneous transluminal angioplasty, and other 
vascular interventions such as percutaneous translumi- 
nal angioplasty or bypass grafting of aorta peripheral 
vessels.
Screening and Effectiveness
Different population-based screening strategies to 
identify subjects with elevated albuminuria were defined. 
In the current approach, screening was assumed to fol-
low the PREVEND study methodology. In particular, 
all subjects would be invited to send a vial with first 
morning void urine by mail to a central laboratory for 
prescreening of urinary albumin concentration (UAC). 
Only those identified with elevated levels of albumin 
in urine would be invited for confirmatory tests, begin-
ning with collection of two 24-hour urine samples for 
measurement of 24-hour UAE. This confirmation test 
for UAE, which is considered an accepted standard 
method for the measurement of albuminuria,6 was as-
sumed to be conducted in the primary care level.4
The ability of a test to identify individuals of interest 
relies on the test characteristics (eg, sensitivity, specific-
ity), but it is also greatly dependent on the setting in 
which the test is conducted (eg, self-test at home vs 
laboratory test).3,4 In particular, the home setting could 
be considered less than ideal for reliable testing when 
compared with a laboratory. Therefore, for the current 
analysis, it was assumed that individuals first sent their 
urine vials to a central laboratory for prescreening for 
albuminuria; those who tested positive were assumed 
to have been invited for a confirmation test in the pri-
mary care setting.
Given current Dutch discussions and the initial design 
of the PREVEND study,3,20 prescreening for UAC 
≥20 mg/L was investigated in the base-case analysis to 
preselect subjects for further UAE measurement, and 
those subjects with confirmed microalbuminuria (UAE 
≥30 mg/d) were assumed to receive angiotensin-converting 
enzyme inhibitor (ACEI) treatment. In the base-case 
analysis, this approach was compared with no screening 
and no treatment for the same modeled cohort. By 
explicitly using the PREVEND study data to calculate 
the number of subjects needed to be screened and tested 
to finally identify and treat 1000 subjects with confirmed 
albuminuria, we implicitly accounted for UAC and UAE 
test characteristics (sensitivity and specificity).
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Sensitivity analysis was directed at investigating dif-
ferent time horizons (5, 8, 10, and 15 years). Further 
sensitivity analyses were carried out for several relevant 
input variables. First, a univariate (ie, deterministic) 
sensitivity analysis was conducted for the various cost 
estimates (eg, UAC prescreening, UAE confirmation 
test, treatment, event costs) and estimates concerning 
the effect of pharmacotherapeutic intervention on disease 
progression and occurrence of events.
Furthermore, we conducted a probabilistic sensitivity 
analysis to account for uncertainty in multiple relevant 
LYG). Costs and effects of screening were annually 
discounted according to the Dutch guidelines for phar-
macoeconomic research at 4% and 1.5%, respectively, 
to correct for time preference. All costs were expressed 
in year-2008 euros.36
Costs associated with screening and treatment with 
RAAS agents, costs of hospitalization for CV events, 
and annual dialysis costs are presented in Table I. The 
costs of screening for albuminuria were based on costs 
involved with prescreening on UAC and on confirma-
tory tests in subjects with elevated UAC (measurement 
of UAE in two 24-hour urine samples), including CV 
and renal risk assessment. In particular, these amounted 
to €7 for prescreening and €60 for the confirmation 
test (including 2 primary care visits and two 24-hour 
UAE measurements) among those found UAC positive 
following the prescreening, respectively.12,37 Treatment 
costs were based on the most frequently used RAAS-
intervening agent, enalapril.38,39 Further costs were 
related to the prescription fee and to annual primary 
care costs.
The costs of CV events such as fatal and nonfatal 
myocardial infarction, fatal and nonfatal stroke, coronary 
artery bypass graft surgery, percutaneous transluminal 
angioplasty, and other CV deaths, and other deaths were 
adapted from van Hout and Simoons40 (Table I). A 
weighted mean of the CV costs was calculated using 
observed data regarding events derived from PREVEND. 
The annual costs of current care and dialysis for treat-
ment of end-stage renal disease were based on a study 
of van Os et al,41 representing a weighted mean of active 
hemodialysis, passive dialysis, and peritoneal dialysis. 
We conservatively included only costs for the first CV 
event and did not include subsequent, potentially prevent-
able events. To be consistent and conservative for dialysis, 
only the costs for 1 year of treatment were included.
Additionally, a formal incremental cost-effectiveness 
analysis and an expected budget impact assessment 
(costs per 1 million people) of different screen-and-treat 
scenarios were performed, the latter based on overall 
Dutch population data.17,30
Scenario Analysis, Deterministic Sensitivity 
Analysis, and Probabilistic Sensitivity Analysis
Scenario analysis was directed at the performance 
of various screen-and-treat strategies based on various 
threshold values for UAC and UAE levels in different 
subgroups based on age (all ages, aged ≥50 years, and 
aged ≥60 years).
Table I.  Costs included in a multistate Markov 
model to simulate the natural course of 
albuminuria-based disease progression 
to dialysis and occurrence of cardiovas-
cular events in the Netherlands.
 Cost, Year-  
Event 2008, €
Screening 
  Prescreening of UAC12 7
  Screening of UAE12,37 60
Treatment 
  Annual treatment with  
   ACE inhibitor38 79
  Annual prescription fee  
   pharmacist37 26
  Annual primary care costs12,37 73
Outcomes 
  Nonfatal cardiovascular  
   events37,40* 7047
  Cardiovascular mortality37,40† 1593
  Dialysis37,41‡ 72,460 
UAC = urinary albumin concentration; UAE = urinary al-
bumin excretion; ACE = angiotensin-converting enzyme.
 * Weighted costs based on occurrence of hospitaliza-
tion for nonfatal myocardial infarction, ischemic 
heart disease, coronary artery bypass grafting, per-
cutaneous transluminal coronary angioplasty, sub- 
arachnoid hemorrhage, intracerebral hemorrhage, 
other unspecif ied intracranial hemorrhage, occlusion 
and stenosis of precerebral arteries, carotid desob-
struction, aorta peripheral bypass surgery, or percu-
taneous transluminal femoral angioplasty.
 †  Weighted costs based on occurrence of hospitaliza-
tion for fatal myocardial infarction, fatal ischemic 
heart disease, or occlusion of cerebral arteries fol-
lowed by death.
 ‡  Only the annual costs for the f irst year of dialysis 
were included in the model.
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versus €1077, respectively (difference of €926). Preven-
tion of CV mortality was estimated to gain 0.0421 
discounted life-year per person identified and treated. 
Consequently, screening for microalbuminuria with 
subsequent treatment of those identified as positive was 
found to be cost-effective, estimated at €22,000/LYG.
Scenario Analyses
Table II shows the cost-effectiveness results for dif-
ferent screen-and-treat scenarios based on variation of 
thresholds for UAC at prescreening to indicate further 
evaluation using UAE and on variation of thresholds 
for UAE confirmation tests resulting in treatment initia-
tion. This table shows data for the overall population, 
as well as for subgroups aged ≥50 and ≥60 years. Limit-
ing screening to subgroups aged ≥50 and ≥60 years 
improved cost-effectiveness considerably with cost- 
effectiveness ratios of respectively €11,500 and 
€7800 per LYG, for the initial set of UAC and UAE 
levels (≥20 mg/L and ≥30 mg/d, respectively). The choice 
for a UAC prescreening threshold in combination with 
the UAE confirmation test for treatment influenced the 
cost-effectiveness. In particular, in combination with UAE 
confirmation tests for treatment of UAE ≥300 mg/d, 
prescreening for UAC ≥20 or ≥100 mg/L seemed to 
result in the most favorable cost-effectiveness outcomes, 
producing values of €20,400 and €14,600/LYG, respec-
tively (Table II).
Sensitivity Analyses
The impact of the different assumptions in the model 
was assessed in a univariate sensitivity analyses for the 
initial (base-case) analysis with prescreening for UAC 
≥20 mg/L and treatment confirmation test for UAE 
≥30 mg/d. These results indicated that a 50% increase 
or decrease of the costs of CV morbidity, CV mortality, 
and dialysis in the base-case analysis with a cost- 
effectiveness ratio of €22,000/LYG resulted in cost-
effectiveness ratios of €17,000 and €26,900/LYG, re-
spectively. The cost-effectiveness outcome appeared to 
be most sensitive to the CV morbidity cost estimate and 
relatively insensitive to the costs associated with dialysis 
because of the low number of incidents of progression 
to dialysis within our time frame of 8 years. Lowering 
or increasing the costs of prescreening on UAC, costs for 
the UAE confirmation test, and costs of ACEI treatment 
by 50% resulted in cost-effectiveness ratios different 
from the base-case cost-effectiveness of €22,000/LYG 
with €19,800/LYG or €24,200/LYG for varying costs 
parameters included in the model. A Monte Carlo 
simulation (10,000 replicates) was used to derive 95% 
CI values for cost-effectiveness and threshold probabili-
ties.42,43 In our model, we included the uncertainty 
around the effect on the transition probabilities between 
all albuminuria-based states (regression and progression 
after initiation of RAAS-intervening agents) and on the 
CV and renal outcomes by drawing from the assumed 
underlying distributions (Appendix I).10,20 In particular, 
for the uncertainty around the transition probabilities for 
the natural course of disease progression, we simulated 
10,000 transition-probability matrices based on the as-
sumption of asymptotic normality of the maximum 
likelihood estimates of the log-transition intensities.30 The 
costs of CV morbidity and CV mortality were also drawn 
from distributions fitted to the observed events and related 
estimated costs from the PREVEND cohort study.20
RESULTS
Base-Case Cost-Effectiveness Analysis
Figure 2 shows the structure of the multistate Markov 
model on which our analyses were based. The 
PREVEND study included 8592 Dutch residents aged 
28 to 75 years at the time of the initial screening. The 
transition probabilities used in the present analysis were 
calculated using the mean (SD) follow-up time from the 
PREVEND cohort of 6.81 (1.67) years. The exact an-
nual transition probabilities are given in Appendix II.
For the base-case scenario, it was estimated that with 
prescreening on UAC ≥20 mg/L and ACEI treatment of 
those subjects with confirmed microalbuminuria (UAE 
≥30 mg/d), a reduced number of CV and renal events 
occurred if compared with no screening. Based on 
8 years of simulation and assuming 1000 subjects identi-
fied with microalbuminuria, it was estimated that 76 
versus 124 CV events would occur, 16 versus 27 CV 
deaths, and 3 versus 5 dialysis cases in the analysis as-
suming screening and treatment versus no screening, 
respectively. Total costs for screening 10,000 subjects 
from the general Dutch population were estimated to 
amount to €114,000 (including €70,000 for UAC pre-
screening and €44,000 for UAE confirmation test among 
those subjects found UAC positive) for the identification 
of 373 subjects with microalbuminuria (UAE ≥30 mg/d). 
Therefore, net costs for identification of 1 subject with 
microalbuminuria based on screening the general Dutch 
population were calculated at €305. Total discounted 
per-person net costs following both the screen-and-treat 
and no-screening strategy were estimated at €2003 
June 2010 1111
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of €16,900 and €10,800/LYG for 10 and 15 years, re-
spectively. These changes in cost-effectiveness outcomes 
may have been the result of the higher numbers of LYGs 
noted for these extended time horizons (Figure 3). 
Additionally, results from the probabilistic sensitivity 
analysis indicated probabilities that cost-effectiveness 
would be below various thresholds for maximum will-
ingness to pay for 1 LYG. In the base-case analysis and 
for maximum willingness to pay of €20,000, €50,000, 
and €80,000/LYG, the probabilities for accepting the 
screen-and-treat procedure were estimated at 54%, 
90%, and 95%, respectively (Figure 4). In age subgroups, 
these probabilities were even higher at 80%, 95%, 
and 97% for ≥50 years, and 88%, 97%, and 98% for 
≥60 years (Figure 4).
Incremental Analysis and Budget Impact Analysis
For the incremental analysis, all possible screen-and-
treat scenarios for all subjects as given in Table II were 
plotted on the cost-effectiveness plane (Figure 5). Here, 
the most favorable scenario with lowest costs and posi-
tive effect was identified (point A in Figure 5). Further-
of UAC prescreening; €20,600/LYG or €23,400/LYG 
for varying costs of the UAE confirmation test; and 
€16,500/LYG or €27,500/LYG for varying ACEI costs, 
respectively. Applying 0% and 4% discount rates to 
both costs and effects resulted in changes of the cost- 
effectiveness ratios in the range €21,400 to €25,200/
LYG. Results obtained after varying the effectiveness of 
ACEI treatment initiated after screening were as follows: 
(1) a 25% change in the applied risk reduction (relative 
risk [RR] = 0.51 or 0.71, instead of 0.60 as assumed in 
the base-case scenario) resulted in cost-effectiveness 
ranging from €15,700 to €32,200/LYG; and (2) a 50% 
change in the applied risk reduction (RR = 0.41 or 0.80, 
instead of the 0.60 as assumed in the base-case scenario) 
resulted in cost-effectiveness ranging from €11,400 to 
€51,800. Changing of the effect of the intervention on 
the progression through albuminuria levels with ±50% 
resulted in only slight differences (€22,000 ± €200/LYG) 
from the base-case cost-effectiveness.
Applying extended time horizons for the analysis 
instead of the 8 years assumed in the base-case scenario 
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Figure 3.  Number of life-years gained (LYGs) per 1000 subjects identified and treated with renin–angiotensin–
aldosterone system–intervening agents in a multistate Markov model to simulate the natural course 
of albuminuria-based disease progression to dialysis and occurrence of cardiovascular events in the 
Netherlands.
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Figure 5 shows that scenario E (UAC ≥100 mg/L and 
UAE ≥15 mg/d) was dominated by a combination of 
scenarios C and E. Scenario F (UAC ≥20 mg/L and UAE 
≥15 mg/d) was similarly dominated by a combination 
of scenarios E and G. The shape of Figure 5 and the 
incremental cost-effectiveness results were essentially 
similar for subgroups aged ≥50 and ≥60 years, but the 
efficiency frontier was more favorable when screening 
would be conducted in older subjects. Also, comparing 
points H and I shows that prescreening subjects using 
the UAC of morning urine samples would greatly reduce 
costs without losing considerable effect. Although limit-
ing screening and subsequent treatment to only those 
subjects with macroalbuminuria (points A and B in 
Figure 5) instead of subjects with microalbuminuria 
(points E and G) would modestly lower costs, it would 
also greatly reduce the effect: the slope of the lines for 
the incremental cost-effectiveness analysis (A to B, B to 
C, C to E) are close to the willingness-to-pay threshold 
of €20,000/LYG.
more, the efficiency frontier was derived after excluding 
subsequent scenarios with higher incremental costs and 
lower incremental effects (dominance) and those sce-
narios that were subject to higher costs and higher in-
cremental cost-effectiveness (extended dominance).44 
For all subjects, the resulting formal efficiency frontier 
is composed by options for screening on macroalbu-
minuria (points A and B in Figure 5); by screening 
options for microalbuminuria (points C, E, and G in 
Figure 5); and by screening options for UAE ≥15 mg/L 
(points H and I in Figure 5). In particular, the base-case 
analysis with screening for microalbuminuria was on 
the frontier of efficiency. After exclusion of 6 scenarios 
that were subject to strict dominance (no prescreening 
and UAE ≥30 mg/d; no prescreening and UAE ≥300 mg/d; 
UAC ≥10 mg/L and UAE ≥300 mg/d; UAC ≥20 mg/L 
and UAE ≥300 mg/d; UAC ≥200 mg/L and UAE 
≥15 mg/d; and UAC ≥200 mg/L and UAE ≥30 mg/d), 
2 scenarios with low thresholds for screening for albu-
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Figure 4.  Cost-effectiveness acceptability curves for screen-and-treat intervention directed at microalbumin- 
uria compared with no screening in a multistate Markov model to simulate the natural course of 
albuminuria-based disease progression to dialysis and occurrence of cardiovascular events in the 
Netherlands.
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respectively. Budget impact increased for scenarios di-
rected at those aged ≥50 years (€68.8 million per million 
subjects screened) or ≥60 years (€80.6 million per mil-
lion subjects screened) with relatively lower screening 
costs and relative higher treatment costs because of the 
higher rate of subjects identified with albuminuria in 
the older population.
DISCUSSION
In this study, we estimated the cost-effectiveness of 
population-based screening for albuminuria to prevent 
renal disease progression and CV events in the general 
population based on data derived from the PREVEND 
study. Screening consisted of a 2-stage approach. First, 
subjects provided (by postal delivery) a vial containing 
a sample of a first morning urine void for measuring 
UAC. Second, if UAC exceeded a predetermined cut-off, 
subjects were invited to collect 24-hour samples to 
Finally, the budget impact was estimated, based on 
a one-off screening without including incident subjects 
with elevated albuminuria using the assumptions in the 
base-case scenario (UAC ≥20 mg/L and UAE ≥30 mg/d). 
Budget impact was estimated at €50.2 million per mil-
lion subjects screened over an 8-year period (Figure 6). 
Furthermore, the budget impact estimated over a 1- and 
5-year period after screening was respectively calculated 
at €17.6 million and €38.3 million per million subjects 
screened. Prescreening and screening contributed 13.9% 
and 8.8% to the total costs, respectively. The remaining 
budget was attributable to costs for primary care visits, 
including cost for albuminuria tests and routine blood 
pressure measurements (31.6%) and costs for treatment 
(45.7%). The proportion of total costs attributable to 
screening for the first year after screening were ~2 to 
3 times higher than screening costs over 5 or 8 years, 





























Figure 5.  Incremental cost-effectiveness ratios for screening among all subjects presenting specified screen-
and-treat scenarios in a multistate Markov model to simulate the natural course of albuminuria-
based disease progression to dialysis and occurrence of cardiovascular events in the Netherlands. 
Costs and effects were based on screening 10,000 of the population of all subjects. (A) Urinary al-
bumin concentration (UAC) ≥200 mg/L and urinary albumin excretion (UAE) ≥300 mg/d. (B) UAC 
≥100 mg/L and UAE ≥300 mg/d. (C) UAC ≥100 mg/L and UAE ≥30 mg/d. (D) Extended dominance: 
UAC ≥100 mg/L and UAE ≥15 mg/d. (E) UAC ≥20 mg/L and UAE ≥30 mg/d (base case). (F) Extended 
dominance: UAC ≥20 mg/L and UAE ≥15 mg/d. (G) UAC ≥10 mg/L and UAE ≥30 mg/d. (H) UAC 
≥10 mg/L and UAE ≥15 mg/d. (I) UAE ≥15 mg/d without UAC prescreening. LYG = life-year gained.
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Although we found favorable cost-effectiveness re-
sults for restricted screening in those subjects who were 
older or had higher albuminuria levels, screening in 
selected populations would coincide with lower absolute 
numbers of subjects identified for potential successful 
preventive treatment.19 Thus, scenarios of screening 
directed at macroalbuminuria or within older age groups 
reduce the likelihood that subjects at elevated risk for 
CV and renal disease would be identified and treated 
in an early stage of disease development.3
Using strict health-economic terminology, the initial 
base-case analysis for screening for microalbuminuria 
was on the efficiency frontier. This efficiency frontier 
consisted of all strategies that were most likely to be 
accepted based on their cost-effectiveness outcome. 
Thus, the extended dominated strategies that involved 
higher costs and/or relatively lower effects of screening 
for elevated albuminuria were excluded. These strategies 
consisted of clinically irrational or irrelevant options 
for population-based screening. This is important, al-
though we note that it has been previously argued that, 
in general, dominated strategies should not automati-
cally be excluded for further decision-making or con-
sideration, but rigorous application of health-economic 
decision rules might suggest this would be the proper 
course of action.45 On the other hand, consistent pat-
terns for all subjects and age subgroups suggest that the 
current alternatives on the efficiency frontier are most 
likely to represent the most favorable strategies. In 
particular, screening for microalbuminuria was associ-
ated with relatively high incremental effects for relatively 
low additional costs and could therefore be considered 
to potentially reflect the optimal choice.
Only 2 published studies have previously attempted 
to estimate the cost-effectiveness of population-based 
screening and treatment for albuminuria.12,17 Boulware 
et al16 investigated cost-effectiveness of initial dipstick 
screening for proteinuria in the general population, with 
follow-up proteinuria confirmation tests to determine 
the need to initiate ACEI treatment. Boulware et al 
reported higher cost-effectiveness rates than those noted 
in the present model analysis, varying from US $53,400 
to $282,800 per quality-adjusted life-year gained. In 
particular, these higher cost-effectiveness rates were due 
to the method of screening (using dipsticks that are only 
positive in case of proteinuria [ie, macroalbuminuria at 
UAC ≥20 mg/L]), which resulted in fewer subjects 
identified compared with screening for albuminuria by 
nephelometry, as in PREVEND,20 which can also mea-
determine UAE. The cost-effectiveness of our base-case 
approach, being a 2-stage screening of the general 
population for microalbuminuria (UAC ≥20 mg/L and 
UAE ≥30 mg/d) followed by ACEI treatment in those 
found to test positive, was estimated at €22,000/ 
LYG. Limiting screening to only those aged ≥50 or 
≥60 years resulted in a more favorable cost-effectiveness 
ratio. Also, we found a great likelihood that the base-
case screen-and-treat procedure would be cost-effective 
according to the different willingness-to-pay thresholds 





Visits to primary care providers
Figure 6.  Distribution of the total estimated bud-
get impact of €50.2 million over 8 years 
per million subjects screened for albu-
minuria in the base-case analysis (all 
subjects, prescreening of the first morn-
ing urine void for urinary albumin con-
centration ≥20 mg/L and confirmation 
in two 24-hour urine voids with urinary 
albumin excretion ≥30 mg) in a multi-
state Markov model to simulate the 
natural course of albuminuria-based 
disease progression to dialysis and oc-
currence of cardiovascular events in the 
Netherlands.
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at microalbuminuria would have benefited from an 
extended lifetime time horizon (ie, inclusion of more 
LYGs through preventing a CV death in younger sub-
jects) and inclusion of all relevant subsequent events 
over the full span of the lifetime. This means that our 
results would be expected to be a conservative estimate. 
At the same time, our results are based on consistent 
use of treatment and do not account for therapy adher-
ence, but effectiveness results measured among individu-
als with albuminuria in a real-life setting implicitly 
include nonadherence34; current cost-effectiveness results 
could be overestimated by not explicitly accounting for 
nonadherence.
Inclusion of the full benefits is a prerequisite for ade- 
quate cost-effectiveness analysis. Furthermore, random-
ized clinical trial data may not perfectly reflect general 
clinical practice circumstances (eg, selected populations, 
fixed doses). Therefore, it is important to also take data 
into account that may better reflect clinical practice. 
The strengths of our study are that we used population- 
based observational data, rather than efficacy data from 
clinical trials. Use of such heterogeneous (ie, general) 
population data, rather than data from a controlled 
setting, gives the opportunity to evaluate the real-life 
natural course of albuminuria-related renal disease 
progression and occurrence of CV and renal events.47 
The population data that are used concern a cohort 
with extensive information on risk factors, medication 
use, and various outcome measures. These data were 
collected prospectively and based on objective data from 
independent databases, thereby minimizing selection, 
recall bias, or both. Finally, albuminuria was measured 
quantitatively with nephelometry and assessed in a first 
morning urine sample (prescreening) and confirmed in 
2 consecutive 24-hour urine collections (actual screening). 
This is considered an accepted standard approach for 
assessing albuminuria.6,20 It also allows the investigation 
of the cost-effectiveness of different screening scenarios 
using various thresholds to define abnormal albuminuria 
levels.
Several studies have reported that microalbuminuria 
was associated with significantly worse CV (2-fold in-
crease in UAC associated with a 30% increase in CV 
mortality) and renal disease prognosis (diminished renal 
function; P = 0.001).48,49 Our favorable cost-effectiveness 
results for screening for microalbuminuria are promis-
ing. In particular, prescreening for UAC is an efficient 
tool for decreasing the costs of population-based screen-
ing for elevated albuminuria. Overall, these results 
sure low amounts of urinary albumin loss (ie, microal-
buminuria at UAC ≥20 mg/L). Consequently, given such 
an approach, there would be higher costs to identify 
one subject who met the predetermined threshold.16 
Moreover, Boulware et al took only those savings and 
health gains into account that were related to averted 
deaths and end-stage renal disease, whereas we focused 
on the savings in the prevention of both CV events and 
renal disease.16,17 If, in our study, we had chosen to 
consider a screen-and-treat scenario directed only at 
greatly elevated levels of albuminuria (proteinuria) and 
included savings and health gains for end-stage renal 
disease without considering CV events, results would have 
been expected to corroborate the findings of Boulware et 
al in that such a favorable cost-effectiveness for early 
identification and treatment of proteinuria for the general 
population would not have existed.4,16 Only one other 
published study addressed this issue, suggesting (based on 
results from a small-scale randomized clinical trial) favor-
able cost-effectiveness for screening the general popula- 
tion for elevated albuminuria to prevent albuminuria- 
associated outcomes by initiating ACEI treatment in 
identified subjects.12 Our analysis adds that if observa-
tional data on both CV events and renal disease events 
are considered, population-based screening for microal-
buminuria with subsequent ACEI treatment would yield 
favorable cost-effectiveness.
Our analysis has limitations. Inherent to the fact that 
we used a time horizon of 8 years, dialysis (being a rare 
complication as a first event) was not found in many 
patients. This could be partially explained by a compet-
ing risk for CV events, meaning that subjects would 
generally be at higher initial risk for a CV event compared 
with the risk of renal disease events (eg, dialysis) that 
take more time to develop.46 Also, our current approach 
assumes a one-off screening without repeated screening. 
Therefore, only those subjects with elevated albuminuria 
(eg, microalbuminuria) would be included at any given 
moment of screening without identifying incident cases 
in the following years. Future cost-effectiveness studies 
should analyze the influence of applying intervals for 
repeated screening, which requires inclusion of more 
specific data on the natural course of disease develop-
ment (eg, age-specific incidence of microalbuminuria). 
Finally, although varied in the sensitivity analysis, the 
applied time horizon of 8 years was not a lifetime ho-
rizon (as is often recommended for health-economic 
analyses). On the other hand, one could argue that the 
cost-effectiveness of a screen-and-treat strategy directed 
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should lead to increased awareness of the importance 
of albuminuria measurements in clinical practice and 
offer decision-makers new tools to consider the potential 
of population-based screening directed at albuminuria.14 
We should also be aware of the limited health care 
budgets and competition with other valuable preventive 
health care interventions. However, it seems that the 
relatively low costs for screening on elevated albuminuria 
and targeted intervention could lead to considerable 
reductions in the burden of illness caused by CV and 
renal disease events over time.
The current analyses were conducted from a health 
care perspective and not from a societal perspective. 
Further research should assess the effects of screening 
on quality-adjusted LYGs and include nonmedical costs 
from the societal perspective. It should also include 
additional gains in terms of early identification of other 
diseases because microalbuminuria may not only follow 
but also precede the development of diabetes or hyper-
tension.50,51 Finally, the cost-effectiveness of repeated 
screening should be calculated.
CONCLUSIONS
Our analyses suggest the potentially favorable cost- 
effectiveness of population-based screening for micro- 
albuminuria in the general Dutch population compared 
with other alternatives, such as screening for macroal-
buminuria. Our findings are based on a previous- 
ly published randomized clinical trial and observational 
findings about the effectiveness and efficacy of anti- 
hypertensives in the prevention of CV and renal events. 
The results offer health care decision-makers new 
tools for considering actual implementation of such 
screening.
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Appendix I.  Parameters of input variables in a multistate Markov model to simulate 
the natural course of albuminuria-based disease progression to dialysis 
and occurrence of cardiovascular events in the Netherlands. All variables 
had a log-normal distribution.
Input Variables Value
Effect parameters, mean (SD), relative risk
  Effect on transition probabilities
     Transition in urinary albumin excretion
      15–30 to <15 mg/d 1.23 (1.07)
      15–30 to 30–300 mg/d 0.74 (1.16)
      30–300 to <15 mg/d 1.41 (1.16)
      30–300 to <15–30 mg/d 1.16 (1.18)
      30–300 to ≥300 mg/d 0.76 (1.51)
      ≥300 to 30–300 mg/d 1.45 (1.50)
  Effect on health outcomes
    Cardiovascular morbidity 0.61 (1.35)
    Cardiovascular mortality 0.61 (1.35)
    Dialysis 0.61 (1.35)
Cost parameters, mean (SD), year-2008 €
  Cardiovascular morbidity 7047 (3140)
  Cardiovascular mortality 1593 (846)
June 2010 1121
C. Boersma et al.
Appendix II.  Annual transition probabilities in a multistate Markov model to simulate the natural course of 
albuminuria-based disease progression to dialysis and occurrence of cardiovascular events in the 
Netherlands.
Annual Transition Probabilities* All Subjects Aged ≥50 Years Aged ≥60 Years
Low normoalbuminuria to high normoalbuminuria 0.016000000 0.021000000 0.021000000
Low normoalbuminuria to microalbuminuria 0.002900000 0.003600000 0.005000000
Low normoalbuminuria to macroalbuminuria 0.000063300 0.000014000 0.000029300
High normoalbuminuria to microalbuminuria 0.040000000 0.046000000 0.055000000
High normoalbuminuria to macroalbuminuria 0.000640000 0.000190000 0.000340000
High normoalbuminuria to low normoalbuminuria 0.073000000 0.054000000 0.038000000
Microalbuminuria to macroalbuminuria 0.000530000 0.007400000 0.011000000
Microalbuminuria to high normoalbuminuria 0.033000000 0.018000000 0.018000000
Microalbuminuria to low normoalbuminuria 0.021000000 0.015000000 0.010000000
Macroalbuminuria to microalbuminuria 0.030000000 0.032000000 0.033000000
Macroalbuminuria to high normoalbuminuria 0.000530000 0.000320000 0.000330000
Macroalbuminuria to low normoalbuminuria 0.000340000 0.000260000 0.000180000
Noncardiovascular mortality
  Low normoalbuminuria 0.002800000 0.007100000 0.013000000
  High normoalbuminuria 0.005500000 0.008600000 0.013000000
  Microalbuminuria 0.014000000 0.022000000 0.026000000
  Macroalbuminuria 0.023000000 0.047000000 0.075000000
Cardiovascular morbidity
  Low normoalbuminuria 0.003800000 0.008300000 0.012000000
  High normoalbuminuria 0.010000000 0.020000000 0.026000000
  Microalbuminuria 0.017000000 0.027000000 0.033000000
  Macroalbuminuria 0.032000000 0.051000000 0.060000000
Cardiovascular mortality
  Low normoalbuminuria 0.000260000 0.000690000 0.001200000
  High normoalbuminuria 0.000570000 0.001700000 0.003500000
  Microalbuminuria 0.003200000 0.004900000 0.007100000
  Macroalbuminuria 0.011000000 0.018000000 0.015000000
Dialysis†
  High normoalbuminuria 0.000000296 0 0
  High normoalbuminuria 0.000003730 0 0
  Microalbuminuria 0.000110000 0 0
  Macroalbuminuria 0.004700000 0 0
Low normoalbuminuria = urinary albumin excretion (UAE) 0–15 mg/d; high normoalbuminura = UAE 15–30 mg/d; mi-
croalbuminuria = UAE 30–300 mg/d; and macroalbuminuria = UAE ≥300 mg/d.
 * Natural course of albuminuria-based disease progression to dialysis and occurrence of cardiovascular events.
 †  The few number of patients undergoing dialysis resulted in a low probability of transition to dialysis for all subjects or 
none at all for those aged ≥50 years or ≥60 years.
